


GDC-6599

Cat. No.:	HY-156684	
CAS No.:	2376824-99-4	
Molecular Formula:	C ₂₀ H ₁₉ ClN ₆ O ₃	
Molecular Weight:	426.86	
Target:	TRP Channel	
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (234.27 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		2.3427 mL	11.7134 mL	23.4269 mL
		5 mM		0.4685 mL	2.3427 mL	4.6854 mL
10 mM		0.2343 mL	1.1713 mL	2.3427 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.86 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.86 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	GDC-6599 (Example 8) is an orally active TRPA1 inhibitor. GDC-6599 can be used to study TRPA1-mediated diseases such as pain ^[1] .
IC ₅₀ & Target	TRPA1 ^[1] .

REFERENCES

[1]. Jack Alexander Terrett, et al. Oxadiazole transient receptor potential channel inhibitors. Patent US20190284179A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA